Vivid Vision
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$25.0k | Seed | ||
$700k | Seed | ||
$2.2m | Seed | ||
N/A | Convertible | ||
N/A | N/A | Series A | |
Total Funding | $2.9m |
Recent News about Vivid Vision
EditVivid Vision specializes in developing advanced vision therapy software aimed at treating conditions such as lazy eye (amblyopia), crossed eye (strabismus), and convergence insufficiency. The company serves vision care professionals and patients, offering solutions that can be used both in clinical settings and at home. Operating in the vision care market, Vivid Vision's business model revolves around providing high-quality software and services to improve visual health. Revenue is generated through the sale of their software and related services. However, sales in the United States are currently paused to comply with new regulatory requirements. Despite this, the company remains committed to supporting the creation of guidelines and classifications within the vision care space. Vivid Vision's innovative approach allows patients to continue their vision therapy uninterrupted, even during events like the COVID-19 pandemic, as evidenced by success stories such as that of Willie, a software developer who has seen significant improvements in his vision.
Keywords: vision therapy, amblyopia, strabismus, convergence insufficiency, vision care, software, regulatory compliance, home therapy, clinical treatment, visual health.